Media Coverage 2015... · 14 September 2015 Dementia Consortium funds project focusing on ALS and FTLD Table of coverage Date Publication/Website Title ... 14/09/2015 World News.com

Media Coverage

Zyme Communications Ltd. Registered in England No. 7294918 www.zymecommunications.com Address: St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Tel: +44 (0)7811 996 942. Email:

[email protected] Page 1 of 21

Announcement

14 September 2015

Dementia Consortium funds project focusing on ALS and FTLD

Table of coverage Date Publication/Website Title

15/09/2015 Pharma Times Dementia Consortium funds protein clumps project

16/09/2015 Drug Target Review Dementia Consortium funds project focusing on ALS and

FTLD

18/09/2015 Technology Networks Dementia Consortium Funds Project Focusing on ALS and

FTLD

14/09/2015 Facebook Dementia Consortium Funds Project Focusing on ALS and

FTLD

14/09/2015 Linkedin Dementia Consortium Funds Project Focusing on ALS and

FTLD

14/09/2015 One Nucleus Dementia Consortium funds project focusing on ALS and

FTLD

14/09/2015 Select Science Dementia Consortium Funds Project Focusing on ALS and

FTLD

14/09/2015 Twitter Dementia Consortium funds project focusing on ALS and

FTLD

14/09/2015 World News.com Dementia Consortium MRCT, Cambridge funds ICGEB

project on ALS and FTLD

15/09/2015 Noodls Dementia Consortium MRCT, Cambridge funds ICGEB


15/09/2015 Right Relevance Dementia Consortium funds protein clumps project

17/09/2015 Life Sciences Index Dementia Consortium Funds Project Focusing on ALS and

FTLD

21/09/2015 The Italian Insider Italian team unites with British company to find cure for

dementia

http://www.zymecommunications.com/

mailto:[email protected]

Media Coverage



Date Publication/Website Title

15/09/2015 Pharma Times Dementia Consortium funds protein clumps project

Dementia Consortium funds protein clumps project

The Dementia Consortium is streaming £305,000 into a project aiming to discover new therapeutics for Amyotrophic Lateral Sclerosis and Frontotemporal Lobar degeneration, the most common cause of dementia in people aged under 50. Both conditions are characterised by the build-up of protein clumps, which can disrupt vital nerve cell communication and eventually cause nerve cell death. The project aims to identify new agents able to clear the misfolded protein TDP-43, which has shown promise as a target in early research, potentially forming the basis of future drug development programmes. With cash from the Dementia Consortium, a unique charity-private £3-million partnership between Alzheimer’s Research UK, MRC Technology and the pharmas Eisai and Lilly, researchers at non-profit group the International Centre for Genetic Engineering and Biotechnology in Trieste will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of TDP-43. In partnership with MRC Technology, the researchers will then test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms of ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD. “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function,” said Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, noting that the funding “will allow us to progress our research in collaboration with MRC Technology to the next stage”.



Media Coverage




14/09/2015 Select Science Dementia Consortium Funds Project Focusing on ALS and

FTLD

Dementia Consortium Funds Project Focusing on ALS and FTLD

Project will identify new potential therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD)

The Dementia Consortium has awarded £305,000 of funding to a project identifying new

therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD).

A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste,

Italy will join forces with London-based MRC Technology to take on the project, with funding

provided by Alzheimer’s Research UK.

While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the

most common cause of dementia in people under the age of 50, experience different symptoms,

both diseases are associated with the same biological processes. Both are characterized by the build-

up of ‘protein clumps’ – aggregates of misfolded versions of a protein called TAR DNA-binding

protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause

nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC

Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have

set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded

proteins, which could form the basis of future much-needed drug development programs.

Using new investment from the Dementia Consortium, a unique charity-private partnership between

Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly,

researchers at ICGEB will develop assays and perform high-content screening to test libraries of

potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise

across the continent, the two research teams will work in partnership to test promising drugs in cells

and animals, to understand how they work and explore whether they can improve symptoms of ALS

and FTLD.



Media Coverage



Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our

initial research into TDP-43 has showed promising results, with some compounds able to enhance

aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us

to progress our research in collaboration with MRC Technology to the next stage.”

Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of

ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and

translation, means we can progress promising science from academia towards effective new

treatments for patients.”

Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of

dementia, but one that disproportionately impacts people under 65. Typical symptoms include

behavioral and personality changes, as well as a lack of social awareness. Managing these symptoms

can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell

damage in the brain. By combining expertise through the Dementia Consortium, we hope to

accelerate progress from academic laboratories across the world into much sought-after treatments

in the clinic.”



Media Coverage




18/09/2015 Technology Networks Dementia Consortium Funds Project Focusing on ALS and

FTLD

Dementia Consortium Funds Project Focusing on ALS and FTLD Project will identify new potential therapeutics for Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.

The Dementia Consortium has awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD). A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both are characterized by the build-up of ‘protein clumps’ - aggregates of misfolded versions of a protein called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins, which could form the basis of future much-needed drug development programmes. Using new investment from the Dementia Consortium, a unique charity-private partnership between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise across the continent, the two research teams will work in partnership to test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms of ALS and FTLD. Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage.”



Media Coverage



Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and translation, means we can progress promising science from academia towards effective new treatments for patients.” Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic.” The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia. The Dementia Consortium is open to global research teams with innovative targets that need accelerating through the drug discovery process.



Media Coverage




14/09/2015 One Nucleus Dementia Consortium funds project focusing on ALS

and FTLD

Dementia Consortium funds project focusing on ALS

and FTLD

London, UK, 14 September 2015: The Dementia Consortium has awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD). A team at the International Centre for Genetic Engineering and

Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both are

characterised by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein

called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins, which could form the basis of future much-needed drug development programmes.

Using new investment from the Dementia Consortium, a unique charity-private partnership between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting expertise across the continent, the two research teams will work in partnership to test promising drugs in cells and animals, to understand how they work and explore whether they can improve symptoms

of ALS and FTLD.

Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented: “Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage.”

Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: “Combining the experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug discovery and translation, means we can progress promising science from academia towards effective new treatments for patients.” Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include

behavioural and personality changes, as well as a lack of social awareness. Managing these

symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we



Media Coverage



hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic.” The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. By uniting expertise, this focused cash injection will bridge the gap between academic research and the

pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia. The Dementia Consortium is open to global research teams with innovative targets that need accelerating through the drug discovery process. For further information please visit http://www.dementiaconsortium.org/.



Media Coverage




16/09/2015 Drug Target Review Dementia Consortium funds project focusing on ALS and

FTLD

Dementia Consortium funds project focusing on

ALS and FTLD

The Dementia Consortium has awarded £305,000 of funding to a project

identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS)

and Frontotemporal Lobar degeneration (FTLD).

A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste

will join forces with MRC Technology to take on the project, with funding provided by Alzheimer’s

Research UK.

While people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD

experience different symptoms, both diseases are associated with the same biological processes. Both

are characterised by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein

called TAR DNA-binding protein 43 (TDP-43). This build-up can disrupt vital nerve cell

communication and eventually cause nerve cell death. Sadly, no treatments exist to halt the spread of

damage in these diseases. MRC Technology and ICGEB have set out to identify agents capable of

clearing misfolded proteins, which could form the basis of future much-needed drug development

programmes.

Initial research into TDP-43 showed promising results

Using new investment from the Dementia Consortium, a unique £3m drug discovery collaboration

between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and

Lilly, researchers at ICGEB will develop assays and perform high-content screening to test libraries of

potential compounds for their ability to clear clumps of misfolded TDP-43. The two research teams

will work in partnership to test promising drugs in cells and animals, to understand how they work

and explore whether they can improve symptoms of ALS and FTLD.

Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB, commented, “Our

initial research into TDP-43 has showed promising results, with some compounds able to enhance

aggregate clearance by more than 50% and fully restore TDP 43 function.”

Dr Justin Bryans, Director of Drug Discovery at MRC Technology, said, “Combining the experience

of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise in drug

discovery and translation, means we can progress promising science from academia towards effective

new treatments for patients.”



http://www.mrctechnology.org/

Media Coverage



Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added, “FTLD is a rare form of

dementia, but one that disproportionately impacts people under 65. Typical symptoms include

behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms

can be incredibly challenging and we’ve gone too long without a therapy that can halt nerve cell

damage in the brain. By combining expertise through the Dementia Consortium, we hope to

accelerate progress from academic laboratories across the world into much sought-after treatments in

the clinic.”



Media Coverage




17/09/2015 Life Sciences Index Dementia Consortium Funds Project Focusing on ALS and

FTLD

Dementia Consortium Funds Project Focusing on ALS and

FTLD

The Dementia Consortium has awarded £305,000 of funding to a project identifying new

therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration

(FTLD). A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB)

in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with

funding provided by Alzheimer’s Research UK.

Although people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and

FTLD, the most common cause of dementia in people under the age of 50, experience different

symptoms, both diseases are associated with the same biological processes. Both are

characterized by the build-up of ‘protein clumps’ – aggregates of misfolded versions of a protein

called TAR DNA-binding protein 43 (TDP-43).

This build-up can disrupt vital nerve cell communication and eventually cause nerve cell death.

Sadly, no treatments exist to halt the spread of damage in these diseases. MRC Technology and

the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to

tackle this lack of treatments and aim to identify agents capable of clearing misfolded proteins,

which could form the basis of future much-needed drug development programmes.

Using new investment from the Dementia Consortium, a unique charity-private partnership

between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai

and Lilly, researchers at ICGEB will develop assays and perform high-content screening to test

libraries of potential compounds for their ability to clear clumps of misfolded TDP-43. By uniting

expertise across the continent, the two research teams will work in partnership to test promising

drugs in cells and animals, to understand how they work and explore whether they can improve

symptoms of ALS and FTLD.



http://www.lifesciencesindex.com/5956/dementia-consortium-funds-project-focusing-on-als-and-ftld

http://www.lifesciencesindex.com/5956/dementia-consortium-funds-project-focusing-on-als-and-ftld

Media Coverage



Dr Marco Baralle, Group Leader in Biotechnology Development at the ICGEB,

commented: “Our initial research into TDP-43 has showed promising results, with some

compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43

function. This funding will allow us to progress our research in collaboration with MRC

Technology to the next stage.”

Dr Justin Bryans, Director of Drug Discovery at MRC Technology, said: “Combining the

experience of ICGEB and Alzheimer’s Research UK together with MRC Technology’s expertise

in drug discovery and translation, means we can progress promising science from academia

towards effective new treatments for patients.”

Dr Eric Karran, Director of Research at Alzheimer’s Research UK, added: “FTLD is a rare form

of dementia, but one that disproportionately impacts people under 65. Typical symptoms include

behavioural and personality changes, as well as a lack of social awareness. Managing these

symptoms can be incredibly challenging and we’ve gone too long without a therapy that can halt

nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we

hope to accelerate progress from academic laboratories across the world into much sought-after

treatments in the clinic.”

The Dementia Consortium is a unique £3 million drug discovery collaboration between

Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly.

By uniting expertise, this focused cash injection will bridge the gap between academic research

and the pharmaceutical industry in the search for new drugs to slow the development of

neurodegenerative diseases that cause dementia.

The Dementia Consortium is open to global research teams with innovative targets that need

accelerating through the drug discovery process. For further information please

visit http://www.dementiaconsortium.org/.



http://mailtrack.me/tracking/raWzMz50paMkCGV0AGL1ZGN5AwLzMKWjqzA2pzSaqaR9ZwLmAGN5ZGplWay2LKu2pG03ZwN1Zwp4ZQpmCt

Media Coverage




15/09/2015 Noodls Dementia Consortium MRCT, Cambridge funds ICGEB


Dementia Consortium MRCT, Cambridge funds ICGEB


ALS (also known as motor neurone disease or Lou Gehrig's Disease) and FTLD are characterised by the formation of cytoplasmic inclusions of misfolded TAR DNA-binding protein 43 (TDP-43) which affect the function of neurons. MRC Technology (London, UK) and the International Centre

for Genetic Engineering and Biotechnology (ICGEB, Trieste, Italy) aim to identify agents capable of clearing misfolded proteins, which could form the basis of future drug development programmes.

Researchers at ICGEB have developed a novel assay system to test potential drug candidates for

their ability to clear aggregated TDP-43 and will now investigate new active agents and characterise their mechanism of action. MRC Technology will develop cellular assays and carry out High Content Screening using its compound libraries, and hits will be confirmed by ICGEB in both in vitro and in vivo behavioural models.

Marco Baralle, Group Leader, Biotechnology Development, ICGEB, commented: "Our initial research into TDP-43 has showed promising results, with some compounds able to enhance aggregate clearance by more than 50% and fully restore TDP 43 function. This funding will allow us to progress our research in collaboration with MRC Technology to the next stage."

Dr Justin Bryans, Director of Drug Discovery at MRC Technology said: "Combining the experience of ICGEB and Alzheimer's Research UK, and MRC Technology's expertise in drug discovery and translation, means we can progress promising science from academia into effective new

treatments for patients."

Dr Eric Karran, Director of Research at Alzheimer's Research UK, added: "FTLD is a rare form of dementia, but one that disproportionately impacts people under 65. Typical symptoms include behavioural and personality changes, as well as a lack of social awareness. Managing these symptoms can be incredibly challenging and we've gone too long without a therapy that can halt nerve cell damage in the brain. By combining expertise through the Dementia Consortium, we

hope to accelerate progress from academic laboratories across the world into much sought-after treatments in the clinic."

The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer's Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly which aims tol bridge the gap between academic research and the pharmaceutical industry in the search for new drugs to slow the development of neurodegenerative diseases that cause dementia.



Media Coverage




21/09/2015 The Italian Insider Italian team unites with British company to find

cure for dementia

Italian team unites with British company to find cure for dementia

International Centre for Genetic Engineering and Biotechnology in Trieste joins fight to cure dementia

LONDON — The Dementia Consortium awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD) on September 14. A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy will join forces with London-based MRC Technology to take on the project, with funding provided by Alzheimer’s Research UK. Whilst people with ALS (also known as motor neurone disease or Lou Gehrig’s Disease) and FTLD, the most common cause of dementia in people under the age of 50, experience different symptoms, both diseases are associated with the same biological processes. Both consist of the accumulation of “protein clumps”, which can disrupt vital nerve cell communication, and can eventually lead to nerve cell death. Unfortunately, at the current moment in time, no treatments exist to halt the spread of damage in these diseases. MRC Technology and the International Centre for Genetic Engineering and Biotechnology in Trieste have set out to tackle this lack of treatments. The Dementia Consortium is a unique £3m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly. Alzheimer’s Research UK is the UK’s leading charity specialising in seeking preventions, treatments, and ultimately a cure for dementia. It is currently supporting dementia-related research projects that are worth over £26 million in some of the top universities in the United Kingdom.



Media Coverage




15/09/2015 Right Relevance Dementia Consortium funds protein clumps project



Media Coverage



,


14/09/2015 World News.com Dementia Consortium MRCT, Cambridge funds

ICGEB project on ALS and FTLD

Dementia Consortium MRCT, Cambridge funds

ICGEB project on ALS and FTLD ALS (also known as motor neurone disease or Lou Gehrig's Disease) and FTLD are characterised by the formation of cytoplasmic inclusions of

misfolded TAR...



http://wn.com/ALS

http://wn.com/Lou_Gehrig's_Disease

http://wn.com/FTLD

http://wn.com/TAR

Media Coverage




14/09/2015 Facebook Dementia Consortium Funds Project Focusing on ALS

and FTLD



Media Coverage





Media Coverage




14/09/2015 Linkedin Dementia Consortium Funds Project Focusing on ALS and

FTLD



Media Coverage




14/09/2015 Twitter Dementia Consortium funds project focusing on ALS and

FTLD



Media Coverage





Documents

Media Coverage 2015... · 14 September 2015 Dementia Consortium funds project focusing on ALS and FTLD Table of coverage Date Publication/Website Title ... 14/09/2015 World News.com